RE:REAL DEALFrom last quarterly report:
"As of September 30, 2021, the Company had cash, cash equivalents, and short-term investments of $91.6 million. The Company believes it has sufficient cash to support its ongoing clinical programs over the next year, including its immuno-oncology pipeline."
So that is about $3/sh worth of cash if the company folded tomorrow. It's a joke that the market is efficient when you see something like this.
Meanwhile, Chinese residents might benefit first from the development of plinabulin based on the FDA nonsense. Perhaps the FDA should only approve plinabulin for Chinese geneology if they want to be rascist. Their guidance should have been clearly stated and individuals should be able to decide unless the FDA feels the drug has safety issues, but no the safety issue is what plinabulin is achieving. The FDA made what appears to be a political decision.
" ... Hengrui will pay all commercialization costs for all indications of plinabulin, and half of clinical development costs for new indications.
... Wanchunbulin will receive all proceeds from sales of plinabulin products and pay Hengrui a pre-determined percentage of such sales.
... Wanchunbulin received 200M RMB (est. US$30M) upfront, and will be eligible to receive up to 1.1B RMB (est. US$170M) in regulatory and sales milestones."
More upside in the next year assuming Hengrui does not renig on the deal, so far no law suits though. Might have to buy more ...